Business Wire

New post-hoc analysis of EMPA-REG OUTCOME® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease

Share

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced results from a new cost-effectiveness analysis of the EMPA-REG OUTCOME® trial in a subgroup of 2,250 people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease.1 Results suggest that treatment with empagliflozin, in addition to standard of care, leads to fewer cardiovascular and renal events, and has the potential to be a cost-effective treatment option for people with type 2 diabetes and diabetic kidney disease from the perspective of payers in the US.1 The results were presented at the ISN World Congress of Nephrology 2019 on 13 April in Melbourne, Australia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190414005012/en/

Currently, there are more than 425 million people living with diabetes worldwide, 30-40 percent of whom are at risk of developing diabetic kidney disease.2,3 Furthermore, one third of people with diabetic kidney disease are at risk of progressing to end-stage kidney disease.3 Type 2 diabetes and diabetic kidney disease independently increase the risk of developing cardiovascular disease, with up to 1.2 million deaths from cardiovascular disease attributed to impaired kidney function.4 This progression of diabetic kidney disease among people with type 2 diabetes imposes substantial medical care costs.4 Typically, high-income countries spend more than 2-3 percent of their annual healthcare budget on the treatment of end-stage kidney disease.4

“Diabetic kidney disease occurs in up to 40 percent of people living with type 2 diabetes, many of whom are at substantial risk of experiencing kidney failure. This places a huge burden, not only on the patient’s life and the lives of their loved ones, but also on healthcare systems,” said Waheed Jamal, MD, Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “We are encouraged by this latest analysis of the EMPA-REG OUTCOME® trial, which suggests that empagliflozin has the potential to be a cost-effective treatment option for people with type 2 diabetes and diabetic kidney disease.”

Empagliflozin is not indicated for the prevention of kidney disease.

Cost effectiveness analysis is a conventional method of evaluating the economic impact of a treatment. The results were garnered using a simulation economic model to predict clinical events and estimated costs for the EMPA-REG OUTCOME® trial subgroup of patients with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease receiving empagliflozin with standard of care versus standard of care alone.1 The modeling and simulation of cost effectiveness was performed using the cost per episode of certain diabetes-related clinical events and health utilities in the US associated with these events. Patients receiving empagliflozin were predicted to experience fewer of these clinical events, including progression of albuminuria (presence of the protein albumin in the urine), composite renal outcomes, hospitalisation for heart failure and cardiovascular deaths. Additionally, patients taking empagliflozin with standard of care were projected to survive 1.37 years longer compared to standard of care alone. This sensitivity analyses showed that, from a US perspective, empagliflozin could be a cost effective option for 99 percent of people with type 2 diabetes and cardiovascular disease at a threshold of $100,000/quality-adjusted life years (QALYs).1*†

“Boehringer Ingelheim and Eli Lilly and Company are committed to addressing the high, unmet clinical need for additional therapies to reduce the risk of kidney disease progression and cardiovascular disease in people with kidney disease, irrespective of whether or not they have diabetes,” said Sherry Martin, M.D., Vice President, Medical Affairs, Lilly Diabetes. “We are looking forward to validating the results presented today with the patient outcomes in EMPA-KIDNEY, which investigates whether empagliflozin could help improve the lives of people living with kidney disease.”

In the landmark EMPA-REG OUTCOME® trial, empagliflozin showed promising results related to the reduction in the relative risk of new onset or worsening kidney disease.5 Based on these insights, Boehringer Ingelheim and Lilly have initiated an academic collaboration with the Medical Research Council Population Health Research Unit at the University of Oxford (MRC PHRU) to conduct EMPA-KIDNEY.6 The study investigates the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death in people with established chronic kidney disease with and without diabetes. Recruitment for the trial started in 2019 with the first results expected in 2022.6

About diabetic kidney disease
Diabetic kidney disease is a progressive decline of kidney function over time that occurs in 30-40 percent of all people with diabetes.3 One third of people with diabetic kidney disease may develop end-stage kidney disease, also known as kidney failure.3 Once end-stage kidney disease is reached, affected individuals have to undergo kidney replacement treatments, such as chronic dialysis or kidney transplantation.7 Since there is currently no approved treatment available to specifically reduce kidney disease progression and cardiovascular death, the overarching unmet medical need for new treatment options for people with kidney disease is evident.

About EMPA-KIDNEY: The study of heart and kidney protection with empagliflozin 6
EMPA-KIDNEY is a multinational randomised, double-blind, placebo-controlled clinical trial. It is designed to evaluate the effect of empagliflozin on clinically relevant outcomes: kidney disease progression and cardiovascular mortality risk. The primary outcome is defined as time to a first event of either a cardiovascular death or kidney disease progression, defined as end-stage kidney disease (the need for kidney replacement therapy such as, dialysis or kidney transplantation), a sustained decline in eGFR to <10mL/min/1.73m2, renal death or a sustained decline of ≥40 percent in eGFR from randomisation. EMPA-KIDNEY includes people with established chronic kidney disease both with and without diabetes receiving current standard of care.

The study is conducted in selected countries representing a global footprint and aims to randomise approximately 5,000 participants to receive either empagliflozin 10mg once daily or placebo, on top of standard of care.

About EMPA-REG OUTCOME ® (NCT01131676) 5
EMPA-REG OUTCOME® was a long-term, multicenter, randomised, double-blind, placebo-controlled trial of more than 7,000 patients from 42 countries with type 2 diabetes and established cardiovascular disease.

The study assessed the effect of empagliflozin (10mg or 25mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.

The overall safety profile of empagliflozin was consistent with that of previous trials.

About Empagliflozin
Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in the label in several countries.8,9,10

Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). Empagliflozin induces changes to the sugar, salt and water metabolism in the body that may contribute to the reductions in cardiovascular death observed in the EMPA-REG OUTCOME® trial.

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/effectiveness-analysis-in-diabetic-kidney-disease-and-type-2-diabetes

* Quality-adjusted life years (QALYs) reflect a patient’s health by weighting life years lived with a health-related utility score, which puts a value on the reduction in a patient’s quality of life

† $100,000/QALY is the threshold for cost-effectiveness analysis in the US. This figure is based on an estimate of the cost-effectiveness of dialysis for chronic kidney disease

Contact information

Boehringer Ingelheim
Dr Petra Kienle
Product Communication Manager
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 143877

Lilly Diabetes
Stephan Thalen
Global Business Communications
Email: stephan.thalen@lilly.com
Phone: +1 (317) 276 8304

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 201916.7.2019 20:05:00 CESTPress release

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2019 financial results will be released on Tuesday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8696029 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, August 1, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the confere

MSCI Schedules Investor Conference Call to Review Second Quarter 2019 Results16.7.2019 14:49:00 CESTPress release

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today it will release its results for second quarter 2019 on Thursday, August 1, 2019. MSCI's senior management will review the second quarter 2019 results on Thursday, August 1, 2019 at 11:00 AM Eastern Time. To listen to the live event, visit the events and presentations section of MSCI's Investor Relations homepage, http://ir.msci.com/events.cfm, or dial 1-877-376-9931 conference ID: 7743929 within the United States. International callers dial 1-720-405-2251 conference ID: 7743929. The earnings release and related investor presentation used during the conference call will be made available on MSCI's Investor Relations homepage. An audio recording of the conference call will be available on our Investor Relations website, http://ir.msci.com/events.cfm, beginning approximately two hours after the conclusion of the live event. Through August 4, 2019,

Keio Plaza Hotel Tokyo Offers “Tea Ceremony Experience and Luxurious Accommodations for Families” Package16.7.2019 14:05:00 CESTPress release

Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will begin offering a special summer accommodation package entitled “Tea Ceremony Experience and Luxurious Accommodations for Families” from July 20 to September 1, 2019. This accommodation package has been specially designed to keep families with children entertained by providing the unique cultural experience of a Japanese tea ceremony as fond memories of their summer vacation at our Hotel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190716005325/en/ With the accommodation package, guests with children could experience unique cultural Japanese tea ceremony to learn how to make a green tea and its history. (Photo: Business Wire) The rooms offered in this accommodation package are the very popular “Two Queen Beds Rooms” located on the “Premier Grand” club floors with use of the Club Lounge included. The rooms are

Andersen Global Enters Senegal, Expands Presence in Africa16.7.2019 13:30:00 CESTPress release

Andersen Global is proud to announce a collaboration agreement with Cabex, one of the oldest legal and tax consulting firms in Senegal. Senegal thus becomes the thirteenth African country where Andersen Global has a member or collaborating firm offering legal services. Located in Dakar, Cabex has been offering services to local and foreign clients from the public and para-public sectors on matters relating to national and international issues for nearly thirty years. “Collaborating with Andersen Global shall expand our international scope and our transborder capabilities while giving us additional opportunities to expand into new markets,” Papa Alassane Ndir, Partner & General Manager at Cabex, said. “Henceforth, we are going to collaborate with many colleagues and experts from around the world and will be in a position to provide our clients more in-depth expertise.” Cherif Diaite, Partner & Technical Manager at Cabex, indicated that, “Owing to the challenge at an international level,

Mercatus Opens UK Office; Hires Chris Webb to Lead European Operations16.7.2019 13:00:00 CESTPress release

Mercatus, a leading asset and investment management platform for alternative investors and asset managers, today announced the opening of its European Headquarters in London, UK and the addition of Chris Webb as Senior Director leading the office in London. Chris was formerly a Global Director of Strategic Business Growth at FIS, with a deep focus on, and expertise in, alternative investments. “As Alternative fund managers and investors across Europe continue to embrace technology – and data – as a competitive weapon to drive future accelerated growth, we’re putting our resources in some of the largest markets. Our London office will be a critical hub for our workings in the UK, expanding upon our other offices in Silicon Valley, New York, Austin, Rome and Pune, India,” said Haresh Patel CEO of Mercatus. “We will continue to expand our local presence across Europe and Asia as our customers have deal and asset management teams in 118 countries with $540B AUM operating within the Mercatu

LivaNova Combats Leg Ischemia with Breakthrough Bidirectional Cannula16.7.2019 13:00:00 CESTPress release

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery. LivaNova Bi-Flow received CE Mark earlier this year and is the only bidirectional arterial cannula designed to prevent leg ischemia during cardiac surgery procedures requiring femoral artery cannulation. In a clinical study, Bi-Flow was easily inserted and removed without complications and was proven to provide simultaneous systemic and distal perfusion of the limb in a safe and reproducible way.1 Leg ischemia is caused by compromised blood flow to a lower limb and can affect up to 11% of patients undergoing complex cardiac surgery procedures.2 Consequences can include higher mortality, higher morbidity and longer hospital stays.3 The first procedure in Europe using a Bi-Flow cannula was performed by Patrick Perier M.D., FACS, at the Cardiovascular Center of Bad Neustadt, Germany. “I truly bel